KLRK1 and cancer: Currently, a phase 1 clinical trial has been launched by Celyad to assess the safety and clinical efficacy of repetitive injections of T cells equipped with a NKG2D-CAR targeting NKG2D-ligands on a variety of different cancer entities including TNBC.